Sun Pharma arm fully acquires PJSC Biosintez after buying 3.04 pc remaining stake for Rs 6 crore
Cash consideration of Rubles 54,194,628.60 equivalent to USD 815,201.99 (about Rs 6 crore) was paid to shareholders who tendered their respective shares in the mandatory tender offer, Sun Pharma said.
NEW DELHI: Drug major Sun Pharmaceutical Industries on Monday said its Netherlands-based arm has fully acquired PJSC Biosintez, Russia by purchasing a 3.04 per cent stake in the company under the mandatory tender offer.
The company's subsidiary - Sun Pharma (Netherlands) BV - already had 96.96 per cent stake in pharma firm PJSC Biosintez prior to the purchase of these shares, Sun Pharma said in a filing to the BSE.
Post the purchase, Sun Pharma (Netherlands) BV's shareholding in the target entity has increased from 96.96 per cent to 100 per cent, it added.
Read Also: SEBI directs Sun Pharma to undergo a forensic audit of financial statements for FY16-18
Cash consideration of Rubles 54,194,628.60 equivalent to USD 815,201.99 (about Rs 6 crore) was paid to shareholders who tendered their respective shares in the mandatory tender offer, Sun Pharma said.
Read Also: Sun Pharma Revital H Woman ads misleading, inadequately substantiated: ASCI
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd